Skip to main content
Clinical Trials/ACTRN12618000713291
ACTRN12618000713291
Recruiting
Phase 3

Efficacy and safety of local anesthesia in patients with head and neck tumors undergoing percutaneous endoscopic gastrostomy (PEG): Lidocaine versus ropivacaine - Prospective, randomized, double blind study

Instituto Português de Oncologia de Lisboa de Francisco Gentil, EPE0 sites30 target enrollmentMay 1, 2018

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Cancer
Sponsor
Instituto Português de Oncologia de Lisboa de Francisco Gentil, EPE
Enrollment
30
Status
Recruiting
Last Updated
6 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
May 1, 2018
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Instituto Português de Oncologia de Lisboa de Francisco Gentil, EPE

Eligibility Criteria

Inclusion Criteria

  • Patients with head and neck tumors referedfor PEG placement without systemic analgesic therapy prior to PEG placement
  • Age 18 years old or older
  • Ability to provide informed consent

Exclusion Criteria

  • Refusal of the patient
  • Inability to provide informed consent
  • Use of systemic analgesics prior to PEG placement
  • Contraindications for PEG placement (patients unable to take PEG, chronic liver disease, presence of ascites, thrombocytopenia (\<50,000 platelets), coagulopathy (INR\> 1\.5\).
  • Allergy to lidocaine, ropivacaine, paracetamol, metamizole magnesium or any of its components and excipients

Outcomes

Primary Outcomes

Not specified

Similar Trials